Maxigen Biotech Inc. (1783.TW)
TWD 46.3
(-0.43%)
TWD 46.3
(-0.43%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 149.85 Million TWD | -12.14% |
| 2022 | 170.56 Million TWD | 69.4% |
| 2021 | 100.68 Million TWD | 30.95% |
| 2020 | 76.88 Million TWD | 1.04% |
| 2019 | 76.09 Million TWD | 64.96% |
| 2018 | 46.12 Million TWD | 119.16% |
| 2017 | 21.04 Million TWD | 286.07% |
| 2016 | -11.31 Million TWD | 81.31% |
| 2015 | -60.52 Million TWD | -111.6% |
| 2014 | -28.6 Million TWD | -703.68% |
| 2013 | -3.55 Million TWD | 66.65% |
| 2012 | -10.67 Million TWD | 74.37% |
| 2011 | -41.63 Million TWD | -34.6% |
| 2010 | -30.93 Million TWD | -523.17% |
| 2009 | 7.31 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 25.33 Million TWD | -24.13% |
| 2024 Q2 | 40.37 Million TWD | 59.35% |
| 2023 Q3 | 55.05 Million TWD | -9.67% |
| 2023 Q1 | 53.4 Million TWD | 1.51% |
| 2023 Q2 | 60.95 Million TWD | 14.13% |
| 2023 FY | 149.85 Million TWD | -12.14% |
| 2023 Q4 | 33.39 Million TWD | -39.34% |
| 2022 Q3 | 53.77 Million TWD | 39.6% |
| 2022 Q1 | 25.66 Million TWD | 54.51% |
| 2022 FY | 170.56 Million TWD | 69.4% |
| 2022 Q4 | 52.6 Million TWD | -2.16% |
| 2022 Q2 | 38.52 Million TWD | 50.1% |
| 2021 Q2 | 20.82 Million TWD | -3.32% |
| 2021 Q4 | 16.6 Million TWD | -51.15% |
| 2021 Q1 | 21.54 Million TWD | -13.61% |
| 2021 FY | 100.68 Million TWD | 30.95% |
| 2021 Q3 | 34 Million TWD | 63.27% |
| 2020 Q4 | 24.93 Million TWD | 105.62% |
| 2020 Q1 | 8.76 Million TWD | -26.56% |
| 2020 Q2 | 15.18 Million TWD | 73.29% |
| 2020 Q3 | 12.12 Million TWD | -20.14% |
| 2020 FY | 76.88 Million TWD | 1.04% |
| 2019 Q4 | 11.93 Million TWD | -48.78% |
| 2019 Q3 | 23.29 Million TWD | -19.26% |
| 2019 FY | 76.09 Million TWD | 64.96% |
| 2019 Q1 | 1.4 Million TWD | 125.4% |
| 2019 Q2 | 28.85 Million TWD | 1958.2% |
| 2018 Q3 | 18.9 Million TWD | 23.97% |
| 2018 Q2 | 15.25 Million TWD | 45.88% |
| 2018 Q4 | 622 Thousand TWD | -96.71% |
| 2018 FY | 46.12 Million TWD | 119.16% |
| 2018 Q1 | 10.45 Million TWD | 61.7% |
| 2017 Q2 | 6.48 Million TWD | 417.8% |
| 2017 FY | 21.04 Million TWD | 286.07% |
| 2017 Q3 | 6.84 Million TWD | 5.46% |
| 2017 Q1 | 1.25 Million TWD | -0.08% |
| 2017 Q4 | 6.46 Million TWD | -5.51% |
| 2016 Q4 | 1.25 Million TWD | 161.9% |
| 2016 Q2 | -1.14 Million TWD | 87.85% |
| 2016 Q1 | -9.39 Million TWD | 63.34% |
| 2016 Q3 | -2.02 Million TWD | -77.41% |
| 2016 FY | -11.31 Million TWD | 81.31% |
| 2015 Q1 | -12.59 Million TWD | 42.2% |
| 2015 Q2 | -16.58 Million TWD | -31.67% |
| 2015 Q3 | -5.71 Million TWD | 65.54% |
| 2015 Q4 | -25.63 Million TWD | -348.75% |
| 2015 FY | -60.52 Million TWD | -111.6% |
| 2014 FY | -28.6 Million TWD | -703.68% |
| 2014 Q2 | -3.36 Million TWD | -1095.56% |
| 2014 Q1 | 338 Thousand TWD | -50.29% |
| 2014 Q4 | -21.78 Million TWD | -475.36% |
| 2014 Q3 | -3.78 Million TWD | -12.54% |
| 2013 Q1 | -3.59 Million TWD | 42.87% |
| 2013 Q3 | -1.12 Million TWD | -332.37% |
| 2013 Q4 | 680 Thousand TWD | 160.34% |
| 2013 FY | -3.55 Million TWD | 66.65% |
| 2013 Q2 | 485 Thousand TWD | 113.48% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 Q4 | -6.29 Million TWD | -70.62% |
| 2012 Q3 | -3.69 Million TWD | 0.0% |
| 2012 FY | -10.67 Million TWD | 74.37% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 FY | -41.63 Million TWD | -34.6% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | -30.93 Million TWD | -523.17% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | 7.31 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 259.91 Million TWD | 42.346% |
| SciVision Biotech Inc. | 199.63 Million TWD | 24.939% |
| Bionime Corporation | -13.33 Million TWD | 1223.398% |
| Pegavision Corporation | 1.98 Billion TWD | 92.436% |
| Visco Vision Inc. | 334.7 Million TWD | 55.229% |